Evotec and co-investors support Dutch Facio Therapies BV with €4.8m to push development of Dux4 inhibitors to treat facioscapulohumeral dystrophy (FSHD), one of the most common forms of muscular dystrophy.
Whether your process includes cell culture or fermentation, autoclavable or single-use vessels, the BioFlo 320 seamlessly combines form and function in one state of the art package.
Belgian Asit Biotech S.A. (formerly Biotech Tools) has announced that its grass pollen allergic rhinitis immunotherapy gp-ASIT+ did reach the primary efficacy endpoint in a Phase III trial but needs confirmation through an additional Phase III study. Market access is receding into the distance.
/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png00Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2017-06-19 08:38:322017-06-19 08:38:32Delay in MAA for Asit Biotechs BTT009
After todays completion of the acquisition of Actelion Ltd by J&J for US$30bn in cash, equivalent to US$280 per share, through the US companys Swiss subsidiary, Janssen Holding GmbH, Actelion will become part of Janssen Pharmaceuticals.
Boehringer Ingelheim has presented detailed pivotal double-blinded Phase III data, which prove comparability of its biosimilar candidate BI695501 to Humira in patients with moderate to severe Rheumatoid Arthritis.
Novartis and Alphabet/Google asset Verily Life Sciences LLC has co-invested into the late stage fund designed to finance programmes with up to €25m post clinical proof of concept.
Germanys Constitutional Court has stopped the government from ratifying the EUs Unitary Patent Package. At the time of the announcement, The German Bundestag and Council of Federal states had already adopted and signed the legislation.
Contract development and manufacturing organisation Recipharm has appointed Shabbir Mostafa as Director, Business Management UK & Ireland. He will be responsible for supporting customers in the UK and Ireland and driving sales of Recipharms manufacturing services.
Evotec invests in Facio Therapies
Latest NewsEvotec and co-investors support Dutch Facio Therapies BV with €4.8m to push development of Dux4 inhibitors to treat facioscapulohumeral dystrophy (FSHD), one of the most common forms of muscular dystrophy.
Eppendorf BioFlo 320 Universal Bioprocess Control Station
ProductsWhether your process includes cell culture or fermentation, autoclavable or single-use vessels, the BioFlo 320 seamlessly combines form and function in one state of the art package.
Delay in MAA for Asit Biotechs BTT009
Latest NewsBelgian Asit Biotech S.A. (formerly Biotech Tools) has announced that its grass pollen allergic rhinitis immunotherapy gp-ASIT+ did reach the primary efficacy endpoint in a Phase III trial but needs confirmation through an additional Phase III study. Market access is receding into the distance.
J&J completes acquisition of Actelion
Latest NewsAfter todays completion of the acquisition of Actelion Ltd by J&J for US$30bn in cash, equivalent to US$280 per share, through the US companys Swiss subsidiary, Janssen Holding GmbH, Actelion will become part of Janssen Pharmaceuticals.
Boehringer Ingelheims Humira biosimilar meets endpoint
Latest NewsBoehringer Ingelheim has presented detailed pivotal double-blinded Phase III data, which prove comparability of its biosimilar candidate BI695501 to Humira in patients with moderate to severe Rheumatoid Arthritis.
Medicxi launches €267m fund
Latest NewsNovartis and Alphabet/Google asset Verily Life Sciences LLC has co-invested into the late stage fund designed to finance programmes with up to €25m post clinical proof of concept.
Germany is blocking EU Unitary Patent Court
Latest NewsGermanys Constitutional Court has stopped the government from ratifying the EUs Unitary Patent Package. At the time of the announcement, The German Bundestag and Council of Federal states had already adopted and signed the legislation.
Recipharm: Strategic appointment
AppointmentsAbivax Ebola antiviral gets financing
Latest NewsFrench virology company Abivac will receive €390,000 for the development of a polyclonal antibody cocktail to fight Ebola.
LowCross-Buffer
ProductsAntibody and sample diluent for minimizing nonspecific binding, cross-reactivities and matrix effects in immunoassays.